Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
NewAmsterdam Pharma Co N.V.
| Metric | NewAmsterdam Pharma Co N.V. NAMSHealthcare |
|---|---|
| Quality Score | 47 / 100 |
| Revenue (latest) | $23M |
| Net income (latest) | −$204M |
| Operating margin | −1002.9% |
| Net margin | −905.7% |
| Return on equity | −29.8% |
| Return on assets | −26.5% |
| Return on capital (ROCE) | −33.0% |
| Debt / equity | 0.13× |
| Revenue growth (YoY) | −50.6% |
| Altman Z″ (distress) | 8.19 |
| Accruals / assets | −7.3% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.